NEW YORK (Genomeweb News) – Harvard University and the Dana-Farber Cancer Institute today said that they have licensed exclusive rights to a high-throughput screening and lead optimization platform for histone deactylase (HDAC) inhibitor compounds to Acetylon Pharmaceuticals.
The partners did not provide details on the screening and optimization platform.
Harvard and Dana-Farber received equity from Acetylon and also will receive downstream royalty and milestone payments, under terms of the licensing agreement.
Boston-based Acetylon was founded on core technology developed at Harvard and Dana-Farber. The firm is developing drug candidates based on next-generation Class II-selective HDAC inhibitors.